trial

Antipsychotic Medication Extended Dosing Study

NCTId NCT00431574
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 120 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2007-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2002-08
Primary completion
2007-06
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
dosing

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Gary Remington, MD PhD FRCPCPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2007-06
Status
COMPLETED
relationships
The graph out of here
drug
dosing
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gary Remington, MD PhD FRCPC
person